FDA ANDA · ANDA201406
AMPICILLIN AND SULBACTAM
Sponsor: ANTIBIOTICE
What this page does not claim
A drug page is a reference view of public FDA data (Drugs@FDA), reproduced as published. SPEQ is not affiliated with the FDA, adds no interpretation to the record, and nothing here is medical, legal, or regulatory advice.
APPLICATION
ANDA201406
TYPE
ANDA
ORIGINAL APPROVAL
2015-12-07
LATEST ACTION
2026-10-19
ROUTE
INTRAMUSCULAR, INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription
Products
AMPICILLIN AND SULBACTAMPrescription
AMPICILLIN SODIUM EQ 2GM BASE/VIAL, SULBACTAM SODIUM EQ 1GM BASE/VIAL · INJECTABLE · INJECTION
AMPICILLIN AND SULBACTAMPrescription
AMPICILLIN SODIUM EQ 1GM BASE/VIAL, SULBACTAM SODIUM EQ 500MG BASE/VIAL · INJECTABLE · INJECTION
Approval history
2026-10-19Labeling · Supplement 11 · standardAP
2026-10-19Labeling · Supplement 9 · standardAP
2024-09-27Labeling · Supplement 1 · standardAP
2024-09-27Labeling · Supplement 7 · standardAP
2024-09-27Labeling · Supplement 3 · standardAP
Source: FDA Drugs@FDA. Browse every approval SPEQ tracks →